Tizalud, tablets 2 mg 30 pcs

Tizalud is a myorelaxant of central action.

The main point of application is in the spinal cord. By stimulating presynaptic alpha 2-adrenoceptors, tizanidine inhibits the release of excitatory amino acids from intermediate neurons of the spinal cord, which leads to inhibition of polysynaptic excitation transmission in the spinal cord. As a consequence, there is a decrease in muscle tone. In addition to the myorelaxant properties, tizanidine also has a central moderately pronounced analgesic effect.

It is effective against acute painful muscle spasms and chronic spasms of spinal and cerebral origin. It reduces spasticity and clonic spasms, as a result of which resistance to passive movements decreases and the volume of active movements increases.

Indications

Spastic condition of skeletal muscles caused by neurological diseases (multiple sclerosis, chronic myelopathy, stroke, degenerative spinal cord diseases).

Painful skeletal muscle spasm caused by spinal disorders (cervical and lumbar syndromes) or following surgery (disc herniation or osteoarthritis of the hip).

Active ingredient

Composition

1 tablet contains:

acting ingredients:

tizanidine – 2 mg.

Auxiliary substances:

anhydrous lactose (lactopress),

microcrystalline cellulose,

sodium carboxymethyl starch (primogel),

magnesium stearate.

How to take, the dosage

For relief of painful muscle spasm: orally, 2-4 mg 3 times a day, in severe cases, an additional 2-4 mg at night.

To treat spasticity due to neurological diseases: the initial dose is 2 mg 3 times a day, then the dose is gradually increased by 2-4 mg at 3-7 day intervals. The optimal daily dose is 12-24 mg in 3-4 doses; the maximum daily dose is 36 mg.

In patients with renal insufficiency: in IQ less than 25 ml/min, the recommended starting dose is 2 mg once daily. Increase the dose gradually, slowly, taking into account tolerability and efficacy.

If a more pronounced effect is needed, it is recommended to first increase the dose prescribed once daily and then increase the frequency of administration.

Interaction

Simultaneous use of tizanidine with fluvoxamine or ciprofloxacin, cytochrome P450 isoenzyme 1A2 inhibitors, leads to a 33-fold increase in AUC of tizanidine. The result of combined use may be clinically significant and prolonged decrease in BP, leading to drowsiness, weakness, slow psychomotor reactions (in some cases up to collapse and loss of consciousness).

The simultaneous use of tizanidine with other CYP1A2-antiarrhythmic inhibitors (amiodarone, mexiletine, propafenone), cimetidine, fluoroquinolones (enoxacin, pefloxacin, norfloxacin), rofecoxib, oral contraceptives, ticlopidine is not recommended.

Antihypertensive drugs (drugs) increase the risk of marked BP decrease and bradycardia. Ethanol, sedative drugs may increase the sedative effect of tizanidine, therefore it is not recommended simultaneous use with other sedative drugs and/or alcohol.

Special Instructions

With caution, use in patients with hepatic and renal dysfunction.

Impact on ability to drive and operate machinery

At the beginning of treatment, if drowsiness occurs, activities requiring high concentration and quick psychomotor reactions should be avoided.

Contraindications

Hypersensitivity to tizanidine.

Hypatic disorders use

Cautious use in patients with liver dysfunction.

Performance in renal dysfunction

Cautious use in patients with renal dysfunction.

Side effects

Nervous system disorders: drowsiness, dizziness, hallucinations, insomnia, sleep disorders.

Cardiovascular system: bradycardia, decreased blood pressure (in some cases pronounced, up to collapse and unconsciousness).

Digestive system disorders: dry mouth, nausea, dyspepsia, increased liver transaminase activity, hepatitis, liver failure.

Musculoskeletal system: muscle weakness.

Other: increased fatigue, hypercreatininemia.

In abrupt withdrawal after prolonged treatment and/or taking high doses of the drug (as well as after simultaneous use with hypotensive drugs): tachycardia, increased blood pressure, in some cases – acute cerebral circulation disorder.

Overdose

Symptoms: nausea, vomiting, marked BP decrease, dizziness, somnolence, miosis, anxiety, respiratory disorders, coma.

Treatment: gastric lavage, administration of activated charcoal, forced diuresis, symptomatic therapy.

Pregnancy use

Since controlled studies of tizanidine use in pregnant women have not been conducted, it should not be used in pregnancy unless the expected benefit to the mother outweighs the possible risk to the fetus.
isanidine is excreted with the breast milk in insignificant amounts.

However, if tizanidine must be used during lactation, discontinuation of breastfeeding should be considered.

Similarities